Nisa Investment Advisors LLC increased its position in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 22.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 30,210 shares of the life sciences company’s stock after buying an additional 5,610 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Integra Lifesciences were worth $1,815,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in IART. Steward Partners Investment Advisory LLC acquired a new stake in Integra Lifesciences in the 2nd quarter valued at approximately $26,000. Zions Bancorporation N.A. grew its stake in shares of Integra Lifesciences by 5.9% in the second quarter. Zions Bancorporation N.A. now owns 4,359 shares of the life sciences company’s stock worth $243,000 after acquiring an additional 242 shares in the last quarter. Cerebellum GP LLC acquired a new position in shares of Integra Lifesciences in the third quarter worth $297,000. ARP Americas LP acquired a new position in shares of Integra Lifesciences in the second quarter worth $302,000. Finally, LPL Financial LLC grew its stake in shares of Integra Lifesciences by 4.4% in the second quarter. LPL Financial LLC now owns 5,754 shares of the life sciences company’s stock worth $319,000 after acquiring an additional 242 shares in the last quarter. 81.91% of the stock is currently owned by hedge funds and other institutional investors.
In other news, VP Kenneth Burhop sold 6,656 shares of the company’s stock in a transaction dated Tuesday, July 30th. The shares were sold at an average price of $63.98, for a total value of $425,850.88. Following the completion of the sale, the vice president now directly owns 15,921 shares of the company’s stock, valued at $1,018,625.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP John Mooradian sold 7,000 shares of the company’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $61.42, for a total transaction of $429,940.00. Following the completion of the sale, the vice president now directly owns 15,410 shares of the company’s stock, valued at $946,482.20. The disclosure for this sale can be found here. Over the last three months, insiders sold 879,421 shares of company stock valued at $53,619,825. 4.50% of the stock is owned by corporate insiders.
Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings results on Thursday, October 24th. The life sciences company reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.03. Integra Lifesciences had a net margin of 6.76% and a return on equity of 16.30%. The firm had revenue of $379.10 million during the quarter, compared to analysts’ expectations of $376.85 million. During the same period in the previous year, the company earned $0.59 earnings per share. Integra Lifesciences’s quarterly revenue was up 3.6% compared to the same quarter last year. As a group, analysts expect that Integra Lifesciences Holdings Corp will post 2.73 earnings per share for the current fiscal year.
Several equities analysts have commented on the stock. ValuEngine upgraded shares of Integra Lifesciences from a “sell” rating to a “hold” rating in a research note on Friday. BTIG Research set a $70.00 price target on shares of Integra Lifesciences and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Royal Bank of Canada set a $66.00 price target on shares of Integra Lifesciences and gave the stock a “hold” rating in a research note on Friday, July 26th. Wells Fargo & Co dropped their price target on shares of Integra Lifesciences from $68.00 to $65.00 and set a “market perform” rating for the company in a research note on Tuesday, October 8th. Finally, Oppenheimer boosted their price target on shares of Integra Lifesciences from $65.00 to $70.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Eight analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $62.42.
Integra Lifesciences Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Featured Article: What is a growth and income fund?
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.